Author:
Qian Maoxiang,Zhang Hui,Kham Shirley Kow-Yin,Liu Shuguang,Jiang Chuang,Zhao Xujie,Lu Yi,Goodings Charnise,Lin Ting-Nien,Zhang Ranran,Moriyama Takaya,Yin Zhaohong,Li Zhenhua,Quah Thuan Chong,Ariffin Hany,Tan Ah Moy,Shen Shuhong,Bhojwani Deepa,Hu Shaoyan,Chen Suning,Zheng Huyong,Pui Ching-Hon,Yeoh Allen Eng-Juh,Yang Jun J.
Abstract
Chromosomal translocations are a genomic hallmark of many hematologic malignancies. Often as initiating events, these structural abnormalities result in fusion proteins involving transcription factors important for hematopoietic differentiation and/or signaling molecules regulating cell proliferation and cell cycle. In contrast, epigenetic regulator genes are more frequently targeted by somatic sequence mutations, possibly as secondary events to further potentiate leukemogenesis. Through comprehensive whole-transcriptome sequencing of 231 children with acute lymphoblastic leukemia (ALL), we identified 58 putative functional and predominant fusion genes in 54.1% of patients (n = 125), 31 of which have not been reported previously. In particular, we described a distinct ALL subtype with a characteristic gene expression signature predominantly driven by chromosomal rearrangements of the ZNF384 gene with histone acetyltransferases EP300 and CREBBP. ZNF384-rearranged ALL showed significant up-regulation of CLCF1 and BTLA expression, and ZNF384 fusion proteins consistently showed higher activity to promote transcription of these target genes relative to wild-type ZNF384 in vitro. Ectopic expression of EP300-ZNF384 and CREBBP-ZNF384 fusion altered differentiation of mouse hematopoietic stem and progenitor cells and also potentiated oncogenic transformation in vitro. EP300- and CREBBP-ZNF384 fusions resulted in loss of histone lysine acetyltransferase activity in a dominant-negative fashion, with concomitant global reduction of histone acetylation and increased sensitivity of leukemia cells to histone deacetylase inhibitors. In conclusion, our results indicate that gene fusion is a common class of genomic abnormalities in childhood ALL and that recurrent translocations involving EP300 and CREBBP may cause epigenetic deregulation with potential for therapeutic targeting.
Funder
National Institutes of Health
American Lebanese Syrian Associated Charities of St. Jude Children's Research Hospital
National Medical Research Council in Singapore
National Cancer Institute
China Scholarship Council and National Natural Science Foundation of China
National Science Foundation of China
Publisher
Cold Spring Harbor Laboratory
Subject
Genetics (clinical),Genetics